World Active Pharmaceutical Ingredients Market - Opportunities and Forecasts, 2017-2023

Pharmaceuticals	LI 161439	Pages: NA	Formats*:
Sep 2017 \| 190 Views	Charts: NA	Tables: NA

Active Pharmaceutical Ingredients are chemically and biologically active components of drugs with direct effect in cure, mitigation, treatment and prevention of diseases. The global API market has witnessed tremendous growth over the last few decades owing to the increased use of drugs and biologics in the treatment of diseases. The increasing adoption of quality standards in API manufacturing such as Good Manufacturing Practices (GMP), current GMP (cGMP), and the global adoption of International Conference on Harmonisation (ICH) guidelines, have helped improve the safety standards. On the other hand, the API industry is facing the challenges such as, shortening the development time, reducing the cost of development, improving the process design and meeting the quality standard without compromising on the profitability. The global API market is likely to be impacted by a large number of innovative drugs going off patent in the recent years. There is an impending need for technological innovations to maintain the profitability in high volume and a low value environment. The major factors driving the market growth are, rising incidences of oncology, cardiovascular, diabetes and lifestyle diseases, rising number of hospitals and diagnostic centers, rising geriatric population in developing countries, increasing healthcare expenditure, increasing disease awareness and education. However, a lack of skilled workforce and limited accessibility of drugs in the developing countries are likely to restrict the market growth.

The Active Pharmaceutical Ingredients (API) Market is segmented on the basis of API type, drug type, manufacturers, therapy area and geography. On the basis of type of API, the market is segmented into, Chemical API and Biological API. The market is further segmented on the basis of type of drugs into; innovative, generic and Over-the-counter (OTC) drugs. According to market players, the market is segmented into Captive (In-house) manufacturer and Merchant (contract) manufacturer. The market is also segmented on the basis of therapy area into; Oncology Drugs, Non-steroidal Anti-inflammatory Drugs, Cardiovascular Drugs, Anti-diabetic Drugs, Neurology Drugs, Musculoskeletal drugs and others. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA. Inorganic growth through merger and acquisition are the key strategies adopted by top industry players. For instance, Ranbaxy recently acquired Sun Pharmaceutical, a move that helped the company emerge as Indias topmost drug manufacturer. Similarly, in July 2014, Hospira completed the acquisition of the API manufacturing facility and associated R&D facility of Orchid Chemicals & Pharmaceuticals Ltd. The companies profiled in this report include, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories, Actavis plc, Lonza Group AG, Hospira Inc. and BASF SE.

KEY MARKET BENEFITS:

Comprehensive analysis of factors that drive and restrict the growth of the Active Pharmaceutical Ingredients (API) Market is provided
The report provides a comprehensive analysis of the current market and estimations through 20142020, which would enable the stakeholders to capitalize on prevailing market opportunities
The projections in the report are made considering the current market trends and market potential for the period of 2014-2020, in terms of value
An in-depth analysis of key segments of the market demonstrate the types of API along with drugs, manufacturers and therapy areas in the global API market
SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
Region-wise Active Pharmaceutical Ingredients (API) market scenario is comprehensively analyzed in the report

KEY MARKET SEGMENTS:

The Active Pharmaceutical Ingredients (API) Market is segmented below:

Active Pharmaceutical Ingredients (API) Market By API Type

Chemical API
Biological API

Active Pharmaceutical Ingredients (API) Market By Drug Type

Innovative Drugs
Generic Prescription
Over-the-counter (OTC) Drugs

Active Pharmaceutical Ingredients (API) Market By Manufacturer

Captive (In-house) manufacturer
Merchant (contract) manufacturer

Active Pharmaceutical Ingredients (API) Market By Therapy Area

Oncology Drugs
Non-steroidal Anti-inflammatory Drugs
Cardiovascular Drugs
Anti-diabetic Drugs
Neurology Drugs
Musculoskeletal drugs
Others

Active Pharmaceutical Ingredients (API) Market By Geography

North America
Europe
Asia-Pacific
LAMEA

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

License Type

Data Pack

Single User PDF

Five User Online/PDF

Enterprise Online/PDF

LICENSE INFO

Users/Sharing

Restricted to one authorized user

Limited to 5 authorized users

Unlimited within company / enterprise

Printing

One Print only